Moxidectin inhibits glioma cell viability by inducing G0/G1 cell cycle arrest and apoptosis.

In conclusion, these results suggest that MOX may inhibit the viability of glioma cells by inducing cell apoptosis and cell cycle arrest, and may be able to function as a potent and promising agent in the treatment of glioma. PMID: 30015956 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30015956?dopt=Abstract

Source: Oncology Reports - July 18, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research